GMED
BULLISH
$93.7
Live
Globus Medical, Inc. · NYSE
Target $110.08
(+17.5%)
$51.79
52W Range
$101.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 28, 2026
Market cap
$12.71B
P/E
23.9
ROE
12.3%
Profit margin
18.3%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
82%
GMED exhibits a stable financial profile with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by a Debt/Equity ratio of 0.03. While the current price of $93.70 trades at a significant premium to its Graham Number ($54.65), it remains well below the growth-based intrinsic value of $115.64. The company demonstrates explosive earnings growth (437% YoY) and a consistent track record of beating analyst estimates over 25 quarters. Despite bearish insider sentiment and weak technical trends, the fundamental growth trajectory and liquidity position make it a strong long-term candidate.
Key Strengths
Exceptional balance sheet with near-zero debt (Debt/Equity 0.03)
Strong liquidity position with a Current Ratio of 4.26
High revenue growth (25.7% YoY) and massive EPS expansion
Consistent earnings beat history (3/4 last 4 quarters, 25.67% avg surprise)
Strong gross margins (68.07%) indicating high pricing power in medical devices
Key Risks
Bearish insider activity with 10 sell transactions and 0 buys
Weak technical trend (10/100) suggesting short-term price pressure
Piotroski F-Score of 4/9 indicates only stable, not strong, operational improvement
High valuation relative to defensive fair value (Graham Number)
Lack of dividend yield for income-seeking investors
AI Fair Value Estimate
Based on comprehensive analysis
$108.5
+15.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
61
Strong
55
92
88
70
0
AI Verdict
Strong Growth / Weak Momentum
Key drivers: Revenue Growth, Balance Sheet Strength, Earnings Surprise History
Confidence
85%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (18.91) is reasonable for the growth rate
- Trades below intrinsic value ($115.64)
Watchpoints
- Trades at a 71% premium to Graham Number ($54.65)
- P/S ratio of 4.33 is moderate to high
Future
92/100
Ref Growth rates
Positives
- YoY Revenue growth of 25.7%
- Massive YoY Earnings growth of 437%
Watchpoints
- Technical trend is currently bearish
Past
88/100
Ref Historical trends
Positives
- 25-quarter track record of stability
- Consistent positive earnings surprises
Watchpoints
- Occasional quarterly misses in 2022
Health
70/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low Debt/Equity (0.03)
- High Current Ratio (4.26)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$93.7
Analyst Target
$110.08
Upside/Downside
+17.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GMED and closest competitors.
Updated 2026-04-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GMED
Globus Medical, Inc.
Primary
|
+30.6% | +61.2% | +29.0% | +48.1% | +11.8% | -3.2% |
|
FMS
Fresenius Medical Care AG
Peer
|
-34.1% | +6.8% | -3.1% | -16.4% | +2.3% | -2.7% |
|
IONS
Ionis Pharmaceuticals, Inc.
Peer
|
+83.9% | +101.9% | +181.4% | +7.4% | +0.5% | +0.5% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+34.2% | +30.1% | +19.1% | -6.2% | -0.5% | +3.0% |
|
MDGL
Madrigal Pharmaceuticals, Inc.
Peer
|
+334.6% | +119.2% | +63.1% | +22.9% | +18.2% | -1.5% |
GME
Globus Medical, Inc.
Primary
5Y
+30.6%
3Y
+61.2%
1Y
+29.0%
6M
+48.1%
1M
+11.8%
1W
-3.2%
FMS
Fresenius Medical Care AG
Peer
5Y
-34.1%
3Y
+6.8%
1Y
-3.1%
6M
-16.4%
1M
+2.3%
1W
-2.7%
ION
Ionis Pharmaceuticals, Inc.
Peer
5Y
+83.9%
3Y
+101.9%
1Y
+181.4%
6M
+7.4%
1M
+0.5%
1W
+0.5%
NBI
Neurocrine Biosciences, Inc.
Peer
5Y
+34.2%
3Y
+30.1%
1Y
+19.1%
6M
-6.2%
1M
-0.5%
1W
+3.0%
MDG
Madrigal Pharmaceuticals, Inc.
Peer
5Y
+334.6%
3Y
+119.2%
1Y
+63.1%
6M
+22.9%
1M
+18.2%
1W
-1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
23.9
Forward P/E
18.91
PEG Ratio
1.49
P/B Ratio
2.77
P/S Ratio
4.33
EV/Revenue
4.16
EV/EBITDA
13.95
Market Cap
$12.71B
Profitability
Profit margins and return metrics
Profit Margin
18.3%
Operating Margin
24.38%
Gross Margin
68.07%
ROE
12.29%
ROA
7.11%
Growth
Revenue and earnings growth rates
Revenue Growth
+25.7%
Earnings Growth
+437.0%
Q/Q Revenue Growth
+25.73%
Q/Q Earnings Growth
+430.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
4.26
Strong
Quick Ratio
2.61
Excellent
Cash/Share
$4.12
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.8B
Gross Margin
68.4%
Op. Margin
21.9%
Net Margin
17.0%
Total Assets
$5.3B
Liabilities
$0.7B
Equity
$4.6B
Debt/Equity
0.16x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
81%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-24
$1.28
+11.0% surprise
2025-11-06
$1.18
+51.1% surprise
2025-08-07
$0.86
+14.9% surprise
Healthcare Sector Comparison
Comparing GMED against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
23.9
This Stock
vs
75.44
Sector Avg
-68.3%
(Discount)
Return on Equity (ROE)
12.29%
This Stock
vs
-88.14%
Sector Avg
-113.9%
(Below Avg)
Profit Margin
18.3%
This Stock
vs
-16.28%
Sector Avg
-212.4%
(Weaker)
Debt to Equity
0.03
This Stock
vs
2.66
Sector Avg
-99.0%
(Less Debt)
Revenue Growth
25.7%
This Stock
vs
124.04%
Sector Avg
-79.3%
(Slower)
Current Ratio
4.26
This Stock
vs
4.47
Sector Avg
-4.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GMED
Globus Medical, Inc.
|
BULLISH | $12.71B | 23.9 | 12.3% | 18.3% | $93.7 | |
|
FMS
Fresenius Medical Care AG
|
BULLISH | $12.44B | 11.56 | 7.9% | 5.0% | $22.77 | Compare |
|
IONS
Ionis Pharmaceuticals, Inc.
|
BEARISH | $12.42B | - | -70.8% | -40.4% | $75.17 | Compare |
|
NBIX
Neurocrine Biosciences, Inc.
|
BULLISH | $13.22B | 28.15 | 16.4% | 16.7% | $131.74 | Compare |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
NEUTRAL | $12.06B | - | -42.5% | -30.1% | $525.67 | Compare |
GMED
Globus Medical, Inc.
BULLISH
Mkt Cap
$12.7B
P/E
23.9
ROE
12.3%
Price
$93.7
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-25 | HULLER KELLY GRACE | General Counsel | Sale | 20,000 | $1,890,000 |
| 2026-02-25 | HULLER KELLY GRACE | General Counsel | Option Exercise | 20,000 | $871,600 |
| 2026-02-12 | HULLER KELLY GRACE | General Counsel | Sale | 10,000 | $876,700 |
| 2026-02-12 | HULLER KELLY GRACE | General Counsel | Option Exercise | 10,000 | $456,400 |
| 2026-01-08 | NORWALK LESLIE V | Director | Sale | 2,000 | $202,200 |
| 2026-01-08 | KLINE KYLE | Chief Financial Officer | Sale | 3,594 | $363,353 |
| 2026-01-08 | KLINE KYLE | Chief Financial Officer | Option Exercise | 3,594 | $186,421 |
| 2025-12-12 | NORWALK LESLIE V | Director | Sale | 4,000 | $355,400 |
| 2025-12-08 | PAUL DAVID C | Officer, Director and Beneficial Owner | Option Exercise | 34,375 | $877,250 |
| 2025-12-01 | KLINE KYLE | Chief Financial Officer | Sale | 18,542 | $1,668,780 |
| 2025-12-01 | KLINE KYLE | Chief Financial Officer | Option Exercise | 18,542 | $1,109,876 |
| 2025-11-25 | HULLER KELLY GRACE | General Counsel | Sale | 7,500 | $675,000 |
| 2025-11-25 | HULLER KELLY GRACE | General Counsel | Option Exercise | 7,500 | $194,700 |
| 2025-11-12 | DAVIDAR DAVID D | Director | Sale | 25,000 | $2,150,005 |
| 2025-11-12 | DAVIDAR DAVID D | Director | Option Exercise | 25,000 | $638,000 |
HULLER KELLY GRACE
General Counsel
2026-02-25
20,000 shares
·
$1,890,000
HULLER KELLY GRACE
General Counsel
2026-02-25
20,000 shares
·
$871,600
HULLER KELLY GRACE
General Counsel
2026-02-12
10,000 shares
·
$876,700
HULLER KELLY GRACE
General Counsel
2026-02-12
10,000 shares
·
$456,400
NORWALK LESLIE V
Director
2026-01-08
2,000 shares
·
$202,200
KLINE KYLE
Chief Financial Officer
2026-01-08
3,594 shares
·
$363,353
KLINE KYLE
Chief Financial Officer
2026-01-08
3,594 shares
·
$186,421
NORWALK LESLIE V
Director
2025-12-12
4,000 shares
·
$355,400
PAUL DAVID C
Officer, Director and Beneficial Owner
2025-12-08
34,375 shares
·
$877,250
KLINE KYLE
Chief Financial Officer
2025-12-01
18,542 shares
·
$1,668,780
KLINE KYLE
Chief Financial Officer
2025-12-01
18,542 shares
·
$1,109,876
HULLER KELLY GRACE
General Counsel
2025-11-25
7,500 shares
·
$675,000
HULLER KELLY GRACE
General Counsel
2025-11-25
7,500 shares
·
$194,700
DAVIDAR DAVID D
Director
2025-11-12
25,000 shares
·
$2,150,005
DAVIDAR DAVID D
Director
2025-11-12
25,000 shares
·
$638,000
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
12 analysts
Wells Fargo
2026-02-26
Overweight
Overweight
Barclays
2026-02-25
Overweight
Overweight
Needham
2026-02-25
Buy
Buy
Needham
2026-01-30
Hold
Buy
Canaccord Genuity
2026-01-09
Buy
Buy
Piper Sandler
2026-01-08
Overweight
Overweight
Canaccord Genuity
2025-12-17
Buy
Buy
RBC Capital
2025-12-17
Outperform
Outperform
Freedom Capital Markets
2025-12-17
Hold
Morgan Stanley
2025-12-02
Overweight
Overweight
Past News Coverage
Recent headlines mentioning GMED from our newsroom.
Newest → oldest
No matching news yet.